{
    "clinical_study": {
        "@rank": "70338", 
        "acronym": "GenTac", 
        "arm_group": [
            {
                "arm_group_label": "Tacni", 
                "arm_group_type": "Experimental", 
                "description": "Tacrolimus administered as generic formulation Tacni in accordance with standard protocol at the transplant center"
            }, 
            {
                "arm_group_label": "Prograf", 
                "arm_group_type": "Active Comparator", 
                "description": "Tacrolimus administered as Prograf in according to standard protocol at the transplant center"
            }
        ], 
        "brief_summary": {
            "textblock": "Test bioequivalence of generic tacrolimus (Tacni), using original tacrolimus (Prograf) as\n      comparator, in elderly (>60 yr) renal transplant recipients"
        }, 
        "brief_title": "Generic Tacrolimus in the Elderly - Prograf\u00ae vs Tacni\u00ae", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "End Stage Renal Disease", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "12-hour pharmacokinetic investigations performed on each formulation in each patient at\n      steady-state. Patients will be randomized with regards to which formulation to start with.\n      1-2 weeks between each PK investigation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Renal transplant recipients that will receive Tac as part of their immunosuppressive\n             therapy.\n\n          -  Recipients 60 years of age or older.\n\n          -  Signed informed consent.\n\n        Exclusion Criteria:\n\n          -  Diabetes mellitus (WHO criteria).\n\n          -  Concomitant treatment with: diltiazem, verapamil, phenytoin, carbamazepin,\n             fluconazole, ketoconazole, voriconazole, erythromycin, clarithromycin."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "26", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_alias": "NCT01798758", 
            "nct_id": "NCT01698541", 
            "org_study_id": "GenTac-12"
        }, 
        "intervention": {
            "arm_group_label": [
                "Tacni", 
                "Prograf"
            ], 
            "intervention_name": "Tacrolimus", 
            "intervention_type": "Drug", 
            "other_name": "Tacrolimus formualted as the generic Tacni"
        }, 
        "intervention_browse": {
            "mesh_term": "Tacrolimus"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Renal", 
            "Transplantation", 
            "Elderly"
        ], 
        "lastchanged_date": "December 9, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Oslo", 
                    "country": "Norway", 
                    "zip": "0027"
                }, 
                "name": "Oslo University Hospital, Rikshospitalet"
            }
        }, 
        "location_countries": {
            "country": "Norway"
        }, 
        "number_of_arms": "2", 
        "official_title": "Generic Tacrolimus in the Elderly - Prograf\u00ae vs Tacni\u00ae", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Norway: Norwegian Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Bioequivalence will be assessed at steady-state by comparing both AUC(0-12) and Cmax ratios for generic:original-ratios and applying the stricter 90-111% bioequivalence criteria.\nAUC(0-12) will be assessed by trapezoidal rule and Cmax will be the highest actually measured concentration.", 
            "measure": "Bioequivalence", 
            "safety_issue": "Yes", 
            "time_frame": "10 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01698541"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Oslo School of Pharmacy", 
            "investigator_full_name": "Anders \u00c5sberg", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Use these new patient data to verify previously developed population pharmacokinetic model for tacrolimus.", 
            "measure": "Population model validation", 
            "safety_issue": "No", 
            "time_frame": "10 weeks"
        }, 
        "source": "University of Oslo School of Pharmacy", 
        "sponsors": {
            "collaborator": {
                "agency": "Oslo University Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Oslo School of Pharmacy", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}